Evidence map›Paper›PMID 35306204›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022

Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection.

Makoto Inada, Masahiro Ishikane, Mari Terada, Akihiro Matsunaga, Kenji Maeda, Noriko Iwamoto, Mugen Ujiie, Satoshi Kutsuna, Shinichiro Morioka, Yukihito Ishizaka and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Makoto InadaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Masahiro IshikaneDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: ishikanemasahiro@gmail.com.
Mari TeradaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for Clinical Science, National Center for Global Health and Medicine, Tokyo, Japan.
Akihiro MatsunagaDepartment of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Kenji MaedaDepartment of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Noriko IwamotoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Mugen UjiieDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Satoshi KutsunaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Professor, Department of Infection Control, Graduate School of Medicine, Osaka University, Osaka, Japan.
Shinichiro MoriokaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Yukihito IshizakaDepartment of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Vice Director General, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Hiroaki MitsuyaDepartment of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Director General, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a case of a 58-year-old Japanese man with a history of 2 previous COVID-19 infections, who received 2 doses of mRNA-1273 vaccine. We are not aware of any previous study regarding antibody tendency after 2 infections and 2 vaccinations. We evaluated his IgG titer of antispike protein and neutralizing activity from the first infection before and after 2 doses of vaccine. Both antispike IgG titer and neutralizing activity showed a tendency to decline almost 1 year after initial infection; they rapidly increased after the first vaccination, and they remained high after the second vaccination. Although this is a single case report, it seems to have generalizability because the findings are consistent with previous reports regarding single infections or 3 doses of vaccination. Our findings suggest that a single booster shot may provide sufficient protection and aid the understanding of immunologic responses of vaccination in patients with COVID-19 with history of re-infection.

Indexed as

COVID-192019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingAntibodies, ViralAntibody FormationCOVID-19 VaccinesHumansImmunoglobulin GMaleMiddle AgedReinfectionSARS-CoV-2Vaccination2019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin Gantispike protein IgG antibodyCOVID-19neutralizing antibodyre-infectionSARS-CoV-2vaccine

Identifiers

PMID35306204
PMCPMC8925083
OpenAlexW4220742422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.